CINECA IRIS Institutional Research Information System

SARACCO, Giorgio Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.402
EU - Europa 10.573
AS - Asia 6.828
SA - Sud America 855
AF - Africa 337
OC - Oceania 234
Continente sconosciuto - Info sul continente non disponibili 21
Totale 34.250
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.727
CN - Cina 3.124
IT - Italia 2.479
DE - Germania 1.342
IE - Irlanda 1.228
SE - Svezia 1.015
FR - Francia 788
GB - Regno Unito 666
SG - Singapore 655
UA - Ucraina 604
IN - India 448
TR - Turchia 428
BR - Brasile 411
JP - Giappone 408
ES - Italia 381
FI - Finlandia 381
CA - Canada 377
KR - Corea 363
PL - Polonia 348
VN - Vietnam 347
MX - Messico 244
AU - Australia 210
ID - Indonesia 199
AT - Austria 170
RU - Federazione Russa 161
TW - Taiwan 157
BE - Belgio 146
HK - Hong Kong 138
EG - Egitto 132
CO - Colombia 128
NL - Olanda 128
GR - Grecia 122
IR - Iran 114
RO - Romania 98
CH - Svizzera 90
CL - Cile 88
PE - Perù 88
PT - Portogallo 86
PK - Pakistan 73
AR - Argentina 68
SA - Arabia Saudita 60
IL - Israele 58
CZ - Repubblica Ceca 56
DK - Danimarca 50
TH - Thailandia 50
HU - Ungheria 46
NO - Norvegia 36
EC - Ecuador 35
ET - Etiopia 31
MY - Malesia 28
PH - Filippine 28
AE - Emirati Arabi Uniti 27
HR - Croazia 27
UZ - Uzbekistan 25
NZ - Nuova Zelanda 24
SI - Slovenia 21
IQ - Iraq 20
EU - Europa 19
MU - Mauritius 19
TN - Tunisia 19
VE - Venezuela 19
KE - Kenya 17
MA - Marocco 17
ZA - Sudafrica 17
BG - Bulgaria 16
NG - Nigeria 15
SK - Slovacchia (Repubblica Slovacca) 14
BD - Bangladesh 13
CR - Costa Rica 12
DO - Repubblica Dominicana 12
LT - Lituania 12
PA - Panama 12
DZ - Algeria 11
JO - Giordania 10
RS - Serbia 10
EE - Estonia 9
GH - Ghana 9
GT - Guatemala 9
LV - Lettonia 9
SD - Sudan 9
BA - Bosnia-Erzegovina 8
UY - Uruguay 8
BO - Bolivia 7
BY - Bielorussia 7
KW - Kuwait 7
MN - Mongolia 6
SN - Senegal 6
AF - Afghanistan, Repubblica islamica di 5
BF - Burkina Faso 5
KZ - Kazakistan 5
LB - Libano 5
LU - Lussemburgo 5
PS - Palestinian Territory 5
ZM - Zambia 5
CI - Costa d'Avorio 4
IS - Islanda 4
MO - Macao, regione amministrativa speciale della Cina 4
CM - Camerun 3
MZ - Mozambico 3
NP - Nepal 3
Totale 34.196
Salva come PNG Salva come JPEG
Città #
Chandler 2.002
Ann Arbor 1.553
Beijing 1.391
Dublin 1.214
Fairfield 780
Houston 624
Torino 586
Redwood City 582
Ashburn 575
Jacksonville 498
Singapore 450
Villeurbanne 406
Wilmington 392
Woodbridge 384
Nyköping 381
Dearborn 374
Princeton 373
Medford 370
Cambridge 259
Seattle 257
Dong Ket 202
Guangzhou 199
Warsaw 190
Shanghai 187
Fremont 182
Pisa 165
Milan 161
Turin 146
Ottawa 139
Nanjing 135
Vienna 132
Boston 131
New York 126
Rome 124
Hangzhou 114
Istanbul 102
Tokyo 100
Taipei 86
Wuhan 81
Brussels 80
London 79
Boardman 77
San Diego 71
Santa Clara 69
Chengdu 68
Toronto 65
Seoul 63
Zhengzhou 63
Jakarta 61
Ankara 56
Lima 56
Santiago 56
Washington 55
Helsinki 51
Madrid 51
Hefei 50
Cairo 49
Norwalk 49
Barcelona 48
Los Angeles 46
Athens 43
Hebei 42
Central 40
Duncan 39
Naples 39
Bogotá 38
Hyderabad 38
Jinan 38
Melbourne 38
Bengaluru 37
Bologna 36
Kunming 36
Berlin 35
Upper Marlboro 35
Medellín 34
Verona 34
West Jordan 34
Chongqing 33
Pune 33
San Mateo 33
São Paulo 33
Amsterdam 32
Fuzhou 32
Nürnberg 32
Izmir 31
Buenos Aires 30
Munich 30
Nanchang 29
Riyadh 28
Rochester 28
Tehran 28
Bucharest 27
Changsha 27
Mountain View 27
Bangkok 26
Falls Church 26
Lahore 26
San Francisco 26
Central District 25
Moscow 25
Totale 18.719
Salva come PNG Salva come JPEG
Nome #
The role of microbiota in autism spectrum disorders 2.052
Serum zonulin in patients with inflammatory bowel disease: a pilot study 1.730
Risk of drug interactions and prescription appropriateness in elderly patients 1.033
Proctitis: a glance beyond inflammatory bowel diseases 1.000
Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection 995
Eosinophilic colitis: clinical review and 2020 update 532
Usefulness of the index of NASH – ION for the diagnosis of steatohepatitis in patients with Non-Alcoholic Fatty Liver: an external validation study 506
Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-α 354
The adherence to the therapy in inflammatory bowel disease: beyond the number of the tablets 326
DURABILITY OF THE RESPONSE TO PEGINTERFERON ALFA2b AND RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS: A COHORT STUDY IN THE ROUTINE CLINICAL SETTING. 314
Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II 309
Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis 304
Prospective randomized trial: Endoscopic follow up 3 vs 6 months after esophageal variceal eradication by band ligation in cirrhosis 303
Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study 302
Fecal calprotectin: beyond intestinal organic diseases 285
Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents 277
Differential diagnosis of pancreatic cysts: A prospective study on the role of intra-cystic glucose concentration 268
Adalimumab trough levels predict Crohn's disease clinical course 266
Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis 256
Risk factors of suspected spondyloarthritis among inflammatory bowel disease patients 250
PDTA MALATTIE GASTROENTEROLOGICHE PERCORSO DIAGNOSTICO TERAPEUTICO ASSISTENZIALE DELLE EPATOPATIE CRONICHE (II) – CIRROSI 235
Favorable short-term outcome of hepatitis C virus–positive liver graft with bridging fibrosis: A plea for very early viral eradication 235
Severe ulcerative colitis: predictors of response and algorithm proposal for rescue therapy 227
Vedolizumab for treatment of chronic refractory pouchitis: a systematic review with pool analysis 219
Liver fibrosis: the 2017 state of art 207
Predictors of risk of fracture in inflammatory bowel diseases: a prospective study using FRAX score 203
Helicobacter pylori infection and ischemic heart disease: could experimental data lead to clinical studies? 199
PDTA MALATTIE GASTROENTEROLOGICHE - PERCORSO DIAGNOSTICO TERAPEUTICO ASSISTENZIALE DELLEEPATOPATIE CRONICHE (I) 190
Management of Pt1 tumours removed by endoscopy during colorectal cancer screening: Outcome and treatment quality indicators 183
Risk of microangiopathy in type 2 diabetes mellitus patients with or without chronic hepatitis C: Results of a retrospective long-term controlled cohort study 181
Awareness of mutational artefacts in suboptimal DNA samples: possible risk for therapeutic choices 179
Prevalence of Micronutrient Deficiency in Patients with Morbid Obesity Before Bariatric Surgery: What About Celiac Disease? 178
Adalimumab versus azathioprine to halt the progression of bowel damage in Crohn’s disease: application of Lémann Index 178
Food supplements, stress and gastrointestinal diseases 178
Is there a link between periampullary diverticula and biliopancreatic disease? An EUS approach to answer the question 174
Dupilumab to target interleukin 4 for inflammatory bowel disease? Hypothesis based on a translational message 174
Pediatric epilepsy and psychiatric comorbidity: could celiac disease diagnosis improve the outcome? 166
AMOXYCILLIN AND METRONIDAZOLE THERAPY FOR HELICOBACTER PYLORI ERADICATION: A 10-YEAR TREND IN TURIN, ITALY 165
Inflammatory bowel disease course in liver transplant versus non-liver transplant patients for primary sclerosing cholangitis: LIVIBD, an IG-IBD study 163
Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single center retrospective study 161
Plasma Selenoprotein P levels are related to adipose tissue insulin resistance, composition of free fatty acids and liver fibrosis in non-diabetic patients with Non Alcoholic Fatty Liver Disease 159
Microscopic colitis in patients with mild duodenal damage: A new clinical and pathological entity ("lymphocytic enterocolitis")? 152
Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection 148
Comment on "Advanced Hepatic Fibrosis in Fatty Liver Disease Linked to Hyperplastic Colonic Polyp" 146
Does Helicobacter pylori infection increase the risk of adult-onset asthma? 145
Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clebopride: a "real world" study by 13C-octanoic acid breath test 141
Progressive increase of matrix metalloprotease-9 and interleukin-8 serum levels during carcinogenic process in human colorectal tract 141
Comments on Sulimani et al.: A weekly 35,000 IU vitamin D supplementation improves bone turnover markers in vitamin D deficient Saudi adolescent females 138
Apparent diffusion coefficient and enhancement patterns in MR imaging as markers of severe or moderate ileum inflammation in Crohn's disease 138
Helicobacter pylori and proton pump inhibitor therapy: One diagnostic method is enough? 135
Comment on Helicobacter pylori seroprevalence and the occurrence and severity of psoriasis 135
Efficacy of infliximab biosimilars in patients with Crohn's disease 135
Angiopoietin like protein 4 (ANGPTL4): a marker of alteration in lipid metabolism, insulin resistance and ectopic fat accumulation 134
Endoscopic ultrasound to diagnose pneumatosis cystoides intestinalis (with video) 133
Helicobacter pyloriinfection and asthma: Is there a direct or an inverse association? A meta-analysis 132
OC. 12.4 PRIMARY SCLEROSING CHOLANGITIS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE: ANALYSIS OF INTESTINAL OUTCOME AFTER LIVER TRANSPLANTATION 132
Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report 132
'e' antigen defective hepatitis B virus and course of chronic infection. 131
Response to: Comment on "efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients" 131
Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis 127
A rare case of gastric fistulization of a main-duct intraductal papillary mucinous neoplasm 126
Absolute quantification of intrahepatic HBV covalently-closed-circular DNA by droplet digital PCR 123
Hepatitis B Core-Related Antigen: A Serum Biomarker for Intrahepatic Covalently-Closed-Circular DNA 123
A 2016 panorama of Helicobacter pylori infection: key messages for clinicians 122
Insulin secretion and decreased glucose clearance are associated with enhanced fibrogenesis and a high risk of disease progression in non-diabetic patients with Non Alcoholic Fatty Liver Disease 122
Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease 122
Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients 122
AISF position paper on HCV in immunocompromised patients 120
Basic and clinical aspects of resistin 116
Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity 115
A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy. 114
Adipose tissue insulin resistance is associated with macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease 113
Higher Efficiency of Percutaneous Microwave (MWA) Than Radiofrequency Ablation (RFA) in Achieving Complete Response in Cirrhotic Patients with Early Hepatocellular Carcinoma 113
Benefit of supplements in functional dyspepsia after treatment of Helicobacter pylori 111
Pharmacological considerations and step-by-step proposal for the treatment of Helicobacter pylori infection in the year 2018 111
Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alpha 2b. 109
The combination of Index of NASH score and liver stiffness improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with NonAlcoholic Fatty Liver Disease. 109
Rifabutin-Based Rescue Therapy for Helicobacter pylori Eradication: A Long-Term Prospective Study in a Large Cohort of Difficult-to-Treat Patients 108
ALL ORAL SOFOSBUVIR-BASED ANTIVIRAL THERAPY IN LIVER TRANSPLANT RECIPIENTS AFFECTED BY MODERATE-SEVERE HEPATITIS C RECURRENCE: PREDICTORS OF VIRAL RESPONSE AND SURVIVAL 107
Bile acids composition modulate insulin resistance in non-diabetic patients with NAFLD 107
The Effect of Viral Clearance Achieved by Direct-Acting Antiviral Agents on Hepatitis C Virus Positive Patients with Type 2 Diabetes Mellitus: A Word of Caution after the Initial Enthusiasm 107
Incidence of type 2 diabetes mellitus and glucose abnormalities in treated patients with chronic hepatitis C infection: Results of a controlled follow-up study. 105
Serum cytokeratin-19 fragments (CYFRA 21-1) for the prediction of overall survival in patients with hepatocellular carcinoma 105
ETIOLOGY OF CHRONIC LIVER DISEASES IN THE NORTHWEST OF ITALY, 1998 THROUGH 2014 104
Negativization of viremia prior to liver transplant reduces early allograft dysfunction in hepatitis C recipients 104
On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases 104
Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma 104
Biomarkers of oncogenesis, adipose tissue dysfunction and systemic inflammation for the detection of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease 103
The clinical role of serum epidermal growth factor receptor 3 in hepatitis c virus-infected patients with early hepatocellular carcinoma 102
Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. 102
Letter: biologics treatment in Crohn's disease and risk of bowel resection-what about the patients who stop anti-TNF therapy? 101
A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. 99
FEASIBILITY AND EFFICACY OF SOFOSBUVIR-BASED ANTIVIRAL THERAPY BEFORE LIVER TRANSPLANTATION TO PREVENT HCV RECURRENCE: A MONOCENTRIC EXPERIENCE 99
Serum levels of protein induced by vitamin K absence or antagonist-II (PIVKA-II) and alpha-fetoprotein (AFP) at baseline predict overall survival in patients with hepatocellular carcinoma (HCC) 99
Absolute quantification of intrahepatic hepatitis B virus covalently-closed-circular DNA by droplet digital PCR technology 98
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 98
Basal values and on treatment decline of hepatitis B core-related antigen are predictive of response to interferon therapy in chronic hepatitis D 96
THE PROGNOSTIC ROLE OF ADALIMUMAB THROUGH LEVELS IN CHRON'S DISEASE 96
Characterization of a novel chemiluminescent enzyme immunoassay for the quantitation of antibodies to hepatitis B core antigen class IgG and correlation with intrahepatic HBV covalently-closed-circular DNA 96
Incidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-Analysis 96
Totale 22.553
Salva come PNG Salva come JPEG
Categoria #
all - tutte 92.971
article - articoli 0
book - libri 0
conference - conferenze 13.198
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 106.169
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.137 0 0 151 343 229 625 477 462 601 540 354 355
2020/20215.090 372 390 433 360 444 462 416 291 461 464 376 621
2021/20226.698 330 299 342 422 371 356 806 716 604 483 1.042 927
2022/20237.619 726 599 372 636 632 1.553 668 509 806 312 482 324
2023/20244.513 494 598 319 349 369 464 244 441 61 293 352 529
2024/2025882 220 528 134 0 0 0 0 0 0 0 0 0
Totale 35.611